Figure 1.
Kaplan-Meier survival curves for OS and TTNT. (A) OS from initiation of daratumumab. (B) TTNT or death from initiation of daratumumab. (C) TTNT or death from initiation of daratumumab for patients with initial dFLC ≥5 mg/dL.
Kaplan-Meier survival curves for OS and TTNT. (A) OS from initiation of daratumumab. (B) TTNT or death from initiation of daratumumab. (C) TTNT or death from initiation of daratumumab for patients with initial dFLC ≥5 mg/dL.